Moreover, preclinical models have shown that genetic or pharmacological inhibition of YY1 sensitizes resistant tumor cells to conventional treatments, highlighting its potential as a biomarker for predicting therapy and a treatment target for overcoming drug resistance [27,28,29]. This evidence concerns the gene YY1 and neoplasm.